{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:50:43Z","timestamp":1781833843401,"version":"3.54.5"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001840","name":"Icelandic Centre for Research","doi-asserted-by":"publisher","award":["2410567"],"award-info":[{"award-number":["2410567"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001840","name":"Icelandic Centre for Research","doi-asserted-by":"publisher","award":["228528-051"],"award-info":[{"award-number":["228528-051"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031490","name":"Krabbameinsf\u00e9lag \u00cdslands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031490","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-026-00934-8","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:18:14Z","timestamp":1777461494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differentiation state affects PD-L1 expression in cutaneous melanoma: a systematic review"],"prefix":"10.1186","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9828-8859","authenticated-orcid":false,"given":"Teitur","family":"S\u00e6varsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8262-900X","authenticated-orcid":false,"given":"Hong Nhung","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5826-7486","authenticated-orcid":false,"given":"Eir\u00edkur","family":"Steingr\u00edmsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5227-8149","authenticated-orcid":false,"given":"Berglind \u00d3sk","family":"Einarsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"6","key":"934_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et\u00a0al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345\u201362. https:\/\/doi.org\/10.1038\/s41571-021-00473-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"934_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/diagnostics13061041","volume":"13","author":"BP Sorroche","year":"2023","unstructured":"Sorroche BP, de TeixeiraJ R, Pereira CAD, Santana IVV, Vujanovic L, de VazquezL V, et\u00a0al. PD-L1 tumor expression as a predictive biomarker of immune checkpoint inhibitors\u2019 response and survival in advanced melanoma patients in Brazil. Diagnostics. 2023;13(6):1041. https:\/\/doi.org\/10.3390\/diagnostics13061041.","journal-title":"Diagnostics"},{"key":"934_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113476","author":"E Ellebaek","year":"2024","unstructured":"Ellebaek E, Khan S, Bastholt L, Schmidt H, Haslund CA, Donia M, et\u00a0al. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. Eur J Cancer. 2024. https:\/\/doi.org\/10.1016\/j.ejca.2023.113476.","journal-title":"Eur J Cancer"},{"issue":"12","key":"934_CR4","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","volume":"23","author":"Z Gatalica","year":"2014","unstructured":"Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et\u00a0al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965\u201370. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-0654.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"934_CR5","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0066","author":"A Javed","year":"2017","unstructured":"Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, et\u00a0al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017. https:\/\/doi.org\/10.2217\/imt-2017-0066.","journal-title":"Immunotherapy"},{"issue":"9","key":"934_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","volume":"97","author":"GJ Kaunitz","year":"2017","unstructured":"Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, et\u00a0al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest. 2017;97(9):1063\u201371. https:\/\/doi.org\/10.1038\/labinvest.2017.64.","journal-title":"Lab Invest"},{"issue":"3","key":"934_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"28","author":"J Madore","year":"2015","unstructured":"Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et\u00a0al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28(3):245\u201353. https:\/\/doi.org\/10.1111\/pcmr.12340.","journal-title":"Pigment Cell Melanoma Res"},{"key":"934_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2483152","author":"GI Papageorgiou","year":"2025","unstructured":"Papageorgiou GI, Skouteris N, Grenzelia M, Maragkoudakis E, Eleftheriou K. Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions? Immunotherapy. 2025. https:\/\/doi.org\/10.1080\/1750743X.2025.2483152.","journal-title":"Immunotherapy"},{"issue":"2","key":"934_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1200\/JCO-24-01572","volume":"43","author":"AM Schmitt","year":"2025","unstructured":"Schmitt AM, Larkin J, Patel SP. Dual immune checkpoint inhibition in melanoma and PD-L1 expression: the jury is still out. J Clin Oncol. 2025;43(2):122\u20134. https:\/\/doi.org\/10.1200\/JCO-24-01572.","journal-title":"J Clin Oncol"},{"key":"934_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01414","volume":"9","author":"S Alavi","year":"2018","unstructured":"Alavi S, Stewart AJ, Kefford RF, Lim SY, Shklovskaya E, Rizos H. Interferon signaling is frequently downregulated in melanoma. Front Immunol. 2018;9:1414. https:\/\/doi.org\/10.3389\/fimmu.2018.01414.","journal-title":"Front Immunol"},{"issue":"1","key":"934_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01963-6","volume":"22","author":"T S\u00e6varsson","year":"2024","unstructured":"S\u00e6varsson T, de Lomana ALG, S\u00e1nchez \u00d3, van Esch V, Ragnarsson GB, Brynj\u00f3lfsson SF, et\u00a0al. Differentiation status determines the effects of IFN\u03b3 on the expression of PD-L1 and immunomodulatory genes in melanoma. Cell Commun Signal. 2024;22(1):618. https:\/\/doi.org\/10.1186\/s12964-024-01963-6.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"934_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, et\u00a0al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305. https:\/\/doi.org\/10.1186\/s40425-019-0770-2.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"934_CR13","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et\u00a0al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u2013201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031.","journal-title":"Cell Rep"},{"issue":"1","key":"934_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9755","volume":"6","author":"S Riesenberg","year":"2015","unstructured":"Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, et\u00a0al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015;6(1):8755. https:\/\/doi.org\/10.1038\/ncomms9755.","journal-title":"Nat Commun"},{"issue":"12","key":"934_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145859","volume":"131","author":"YJ Kim","year":"2021","unstructured":"Kim YJ, Sheu KM, Tsoi J, Abril-Rodriguez G, Medina E, Grasso CS, et\u00a0al. Melanoma dedifferentiation induced by IFN-\u03b3 epigenetic remodeling in response to anti\u2013PD-1 therapy. J Clin Invest. 2021;131(12):e145859. https:\/\/doi.org\/10.1172\/JCI145859.","journal-title":"J Clin Invest"},{"issue":"6","key":"934_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2016.03.009","volume":"37","author":"M H\u00f6lzel","year":"2016","unstructured":"H\u00f6lzel M, T\u00fcting T. Inflammation-induced plasticity in melanoma therapy and metastasis. Trends Immunol. 2016;37(6):364\u201374. https:\/\/doi.org\/10.1016\/j.it.2016.03.009.","journal-title":"Trends Immunol"},{"issue":"7420","key":"934_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et\u00a0al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412\u20136. https:\/\/doi.org\/10.1038\/nature11538.","journal-title":"Nature"},{"issue":"15\u201316","key":"934_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1101\/gad.324657.119","volume":"33","author":"CR Goding","year":"2019","unstructured":"Goding CR, Arnheiter H. MITF\u2014The first 25 years. Genes Dev. 2019;33(15\u201316):983\u20131007. https:\/\/doi.org\/10.1101\/gad.324657.119.","journal-title":"Genes Dev"},{"issue":"5","key":"934_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/pcmr.13053","volume":"35","author":"JS Chauhan","year":"2022","unstructured":"Chauhan JS, H\u00f6lzel M, Lambert JP, Buffa FM, Goding CR. The MITF regulatory network in melanoma. Pigment Cell Melanoma Res. 2022;35(5):517\u201333. https:\/\/doi.org\/10.1111\/pcmr.13053.","journal-title":"Pigment Cell Melanoma Res"},{"key":"934_CR20","doi-asserted-by":"publisher","first-page":"e63093","DOI":"10.7554\/eLife.63093","volume":"10","author":"R Dilshat","year":"2021","unstructured":"Dilshat R, Fock V, Kenny C, Gerritsen I, Lasseur RMJ, Travnickova J, et\u00a0al. MITF reprograms the extracellular matrix and focal adhesion in melanoma. Elife. 2021;10:e63093. https:\/\/doi.org\/10.7554\/eLife.63093.","journal-title":"Elife"},{"issue":"5","key":"934_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et\u00a0al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33(5):890-904.e5. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.017.","journal-title":"Cancer Cell"},{"key":"934_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006766","author":"S Subhadarshini","year":"2023","unstructured":"Subhadarshini S, Sahoo S, Debnath S, Somarelli JA, Jolly MK. Dynamical modeling of proliferative-invasive plasticity and IFN\u03b3 signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-006766.","journal-title":"J Immunother Cancer"},{"key":"934_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174250","author":"A Ahn","year":"2021","unstructured":"Ahn A, Rodger EJ, Motwani J, Gimenez G, Stockwell PA, Parry M, et\u00a0al. Transcriptional reprogramming and constitutive PD-L1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumour necrosis factor signalling pathways. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13174250.","journal-title":"Cancers (Basel)"},{"key":"934_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.930250","author":"P Falletta","year":"2022","unstructured":"Falletta P, Goding CR, Vivas-Garc\u00eda Y. Connecting metabolic rewiring with phenotype switching in melanoma. Front Cell Dev Biol. 2022. https:\/\/doi.org\/10.3389\/fcell.2022.930250.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"934_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/gad.290940.116","volume":"31","author":"P Falletta","year":"2017","unstructured":"Falletta P, Sanchez-del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, et\u00a0al. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev. 2017;31(1):18. https:\/\/doi.org\/10.1101\/gad.290940.116.","journal-title":"Genes Dev"},{"issue":"1","key":"934_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.molcel.2019.10.014","volume":"77","author":"Y Vivas-Garc\u00eda","year":"2020","unstructured":"Vivas-Garc\u00eda Y, Falletta P, Liebing J, Louphrasitthiphol P, Feng Y, Chauhan J, et\u00a0al. Lineage-restricted regulation of SCD and fatty acid saturation by MITF controls melanoma phenotypic plasticity. Mol Cell. 2020;77(1):120-137.e9. https:\/\/doi.org\/10.1016\/j.molcel.2019.10.014.","journal-title":"Mol Cell"},{"issue":"7","key":"934_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"issue":"5","key":"934_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/pcmr.12611","volume":"30","author":"HE Seberg","year":"2017","unstructured":"Seberg HE, Van Otterloo E, Cornell RA. Beyond MITF: multiple transcription factors directly regulate the cellular phenotype in melanocytes and melanoma. Pigment Cell Melanoma Res. 2017;30(5):454\u201366. https:\/\/doi.org\/10.1111\/pcmr.12611.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"934_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.hoc.2020.08.010","volume":"35","author":"SM Ostrowski","year":"2021","unstructured":"Ostrowski SM, Fisher DE. Biology of melanoma. Hematol Oncol Clin North Am. 2021;35(1):29\u201356. https:\/\/doi.org\/10.1016\/j.hoc.2020.08.010.","journal-title":"Hematol Oncol Clin North Am"},{"key":"934_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-030-05070-2_42","volume-title":"Cutaneous melanoma","author":"MR Zaidi","year":"2020","unstructured":"Zaidi MR, Fisher DE, Rizos H. Biology of melanocytes and primary melanoma. In: Zaidi MR, editor. Cutaneous melanoma. Cham: Springer; 2020. p. 3\u201340. https:\/\/doi.org\/10.1007\/978-3-030-05070-2_42."},{"issue":"5","key":"934_CR31","doi-asserted-by":"publisher","first-page":"e0178645","DOI":"10.1371\/journal.pone.0178645","volume":"12","author":"A Collins","year":"2017","unstructured":"Collins A, Ross J, Lang SH. A systematic review of the asymmetric inheritance of cellular organelles in eukaryotes: a critique of basic science validity and imprecision. PLoS ONE. 2017;12(5):e0178645. https:\/\/doi.org\/10.1371\/journal.pone.0178645.","journal-title":"PLoS ONE"},{"key":"934_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et\u00a0al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;29:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"issue":"6","key":"934_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41416-023-02316-9","volume":"129","author":"A Barnwal","year":"2023","unstructured":"Barnwal A, Tamang R, Das S, Bhattacharyya J. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression. Br J Cancer. 2023;129(6):1007\u201321. https:\/\/doi.org\/10.1038\/s41416-023-02316-9.","journal-title":"Br J Cancer"},{"issue":"2","key":"934_CR34","first-page":"530","volume":"11","author":"K Bauer","year":"2021","unstructured":"Bauer K, Berghoff AS, Preusser M, Heller G, Zielinski CC, Valent P, et\u00a0al. Degradation of BRD4\u2014A promising treatment approach not only for hematologic but also for solid cancer. Am J Cancer Res. 2021;11(2):530\u201345.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"934_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep40585","volume":"7","author":"R Berzaghi","year":"2017","unstructured":"Berzaghi R, Maia VSC, Pereira FV, Melo FM, Guedes MS, Origassa CST, et\u00a0al. SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression. Sci Rep. 2017;7(1):40585. https:\/\/doi.org\/10.1038\/srep40585.","journal-title":"Sci Rep"},{"key":"934_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115851","author":"S Bhattacharyya","year":"2024","unstructured":"Bhattacharyya S, O-Sullivan I, Tobacman JK. N-acetylgalactosamine-4-sulfatase (arylsulfatase B) regulates PD-L1 expression in melanoma by an HDAC3-mediated epigenetic mechanism. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25115851.","journal-title":"Int J Mol Sci"},{"issue":"6282","key":"934_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et\u00a0al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227\u201331. https:\/\/doi.org\/10.1126\/science.aac9935.","journal-title":"Science"},{"issue":"1","key":"934_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111559","volume":"28","author":"N Cerioli","year":"2025","unstructured":"Cerioli N, Bououdina W, Mereu A, Natsaridis E, Salsetta J, Cova A, et\u00a0al. Reprogramming the melanoma and immunosuppressive myeloid cells with esomeprazole-loaded PLGA nanoparticles. iScience. 2025;28(1):111559. https:\/\/doi.org\/10.1016\/j.isci.2024.111559.","journal-title":"iScience"},{"key":"934_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101335","volume":"17","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhao M, Zhang L, Shen D, Xu X, Yi Q, et\u00a0al. SNF5, a core subunit of SWI\/SNF complex, regulates melanoma cancer cell growth, metastasis, and immune escape in response to matrix stiffness. Transl Oncol. 2022;17:101335. https:\/\/doi.org\/10.1016\/j.tranon.2021.101335.","journal-title":"Transl Oncol"},{"key":"934_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178008","volume":"1004","author":"J Chen","year":"2025","unstructured":"Chen J, Liang Y, Li J, Wu F, Wu N, Liu S, et\u00a0al. Diosmetin augments BRAF-targeted therapy via concurrent suppression of MAPK and STAT3 pathways in melanoma. Eur J Pharmacol. 2025;1004:178008. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178008.","journal-title":"Eur J Pharmacol"},{"key":"934_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050666","author":"L Chen","year":"2025","unstructured":"Chen L, Liao W, Huang J, Ding Q, Wu J, Zhang Q, et\u00a0al. Natural killer cell activation signature identifies cyclin B1\/CDK1 as a druggable target to overcome natural killer cell dysfunction and tumor invasiveness in melanoma. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18050666.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"934_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/pcmr.12620","volume":"31","author":"Y Chhabra","year":"2018","unstructured":"Chhabra Y, Yong HXL, Fane ME, Soogrim A, Lim W, Mahiuddin DN, et\u00a0al. Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon-gamma response in melanocytic cells. Pigment Cell Melanoma Res. 2018;31(1):51\u201363. https:\/\/doi.org\/10.1111\/pcmr.12620.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"934_CR43","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jid.2021.11.017","volume":"142","author":"K Conway","year":"2022","unstructured":"Conway K, Tsai YS, Edmiston SN, Parker JS, Parrish EA, Hao H, et\u00a0al. Characterization of the CpG island hypermethylated phenotype subclass in primary melanomas. J Invest Dermatol. 2022;142(7):1869-1881.e10. https:\/\/doi.org\/10.1016\/j.jid.2021.11.017.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"934_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1846915","volume":"9","author":"RA de Azevedo","year":"2020","unstructured":"de Azevedo RA, Shoshan E, Whang S, Markel G, Jaiswal AR, Liu A, et\u00a0al. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020;9(1):1846915. https:\/\/doi.org\/10.1080\/2162402X.2020.1846915.","journal-title":"Oncoimmunology"},{"key":"934_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2020.01.016","volume":"474","author":"F Flores-Guzm\u00e1n","year":"2020","unstructured":"Flores-Guzm\u00e1n F, Utikal J, Umansky V. Dormant tumor cells interact with memory CD8(+) T cells in RET transgenic mouse melanoma model. Cancer Lett. 2020;474:74\u201381. https:\/\/doi.org\/10.1016\/j.canlet.2020.01.016.","journal-title":"Cancer Lett"},{"issue":"5","key":"934_CR46","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/jid.2013.490","volume":"134","author":"J Furuta","year":"2014","unstructured":"Furuta J, Inozume T, Harada K, Shimada S. CD271 on melanoma cell is an IFN-\u03b3-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol. 2014;134(5):1369\u201377. https:\/\/doi.org\/10.1038\/jid.2013.490.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"934_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123410","volume":"10","author":"K Gowrishankar","year":"2015","unstructured":"Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-\u03baB. PLoS ONE. 2015;10(4):e0123410. https:\/\/doi.org\/10.1371\/journal.pone.0123410.","journal-title":"PLoS ONE"},{"key":"934_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001866","author":"W Guo","year":"2020","unstructured":"Guo W, Ma J, Guo S, Wang H, Wang S, Shi Q, et\u00a0al. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001866.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"934_CR49","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","volume":"19","author":"X Jiang","year":"2013","unstructured":"Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19(3):598\u2013609. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2731.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"934_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","volume":"6","author":"MH Kim","year":"2018","unstructured":"Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, et\u00a0al. YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol Res. 2018;6(3):255\u201366. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0320.","journal-title":"Cancer Immunol Res"},{"key":"934_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01269-w","volume":"20","author":"Z Li","year":"2020","unstructured":"Li Z, Zhang C, Du JX, Zhao J, Shi MT, Jin MW, et\u00a0al. Adipocytes promote tumor progression and induce PD-L1 expression via TNF-\u03b1\/IL-6 signaling. Cancer Cell Int. 2020;20:179. https:\/\/doi.org\/10.1186\/s12935-020-01269-w.","journal-title":"Cancer Cell Int"},{"key":"934_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.036","volume":"477","author":"T Li","year":"2020","unstructured":"Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, et\u00a0al. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett. 2020;477:19\u201330. https:\/\/doi.org\/10.1016\/j.canlet.2020.02.036.","journal-title":"Cancer Lett"},{"issue":"23","key":"934_CR53","doi-asserted-by":"publisher","first-page":"6755","DOI":"10.1039\/d2bm01354a","volume":"10","author":"Y Li","year":"2022","unstructured":"Li Y, Meng X, Chen G, Hou Y, Wu X, Wang J, et\u00a0al. Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy. Biomater Sci. 2022;10(23):6755\u201367. https:\/\/doi.org\/10.1039\/d2bm01354a.","journal-title":"Biomater Sci"},{"key":"934_CR54","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.actbio.2022.10.008","volume":"154","author":"L Li","year":"2022","unstructured":"Li L, Zhang M, Liu T, Li J, Sun S, Chen J, et\u00a0al. Quercetin-ferrum nanoparticles enhance photothermal therapy by modulating the tumor immunosuppressive microenvironment. Acta Biomater. 2022;154:454\u201366. https:\/\/doi.org\/10.1016\/j.actbio.2022.10.008.","journal-title":"Acta Biomater"},{"issue":"Pt B","key":"934_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111000","volume":"124","author":"X Li","year":"2023","unstructured":"Li X, He L, Ou Y, Wang S, Hu Y, Niu H. Oxymatrine inhibits melanoma development by modulating the immune microenvironment and targeting the MYC\/PD-L1 pathway. Int Immunopharmacol. 2023;124(Pt B):111000. https:\/\/doi.org\/10.1016\/j.intimp.2023.111000.","journal-title":"Int Immunopharmacol"},{"key":"934_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s44178-024-00094-9","author":"T Li","year":"2024","unstructured":"Li T, Xing R, Xiang L, Liu H, Wei J, Lu J, et\u00a0al. MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma. Holistic Integr Oncol. 2024. https:\/\/doi.org\/10.1007\/s44178-024-00094-9.","journal-title":"Holistic Integr Oncol"},{"issue":"5","key":"934_CR57","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","volume":"10","author":"M Lienlaf","year":"2016","unstructured":"Lienlaf M, Perez-Villarroel P, Knox T, Pabon M, Sahakian E, Powers J, et\u00a0al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol. 2016;10(5):735\u201350. https:\/\/doi.org\/10.1016\/j.molonc.2015.12.012.","journal-title":"Mol Oncol"},{"issue":"7","key":"934_CR58","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ymthe.2021.03.013","volume":"29","author":"N Liu","year":"2021","unstructured":"Liu N, Zhang J, Yin M, Liu H, Zhang X, Li J, et\u00a0al. Inhibition of xCT suppresses the efficacy of anti-PD-1\/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol Ther. 2021;29(7):2321\u201334. https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.013. (PubMed PMID: 33744468; PubMed Central PMCID: PMC8261162).","journal-title":"Mol Ther"},{"key":"934_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007146","author":"N Liu","year":"2023","unstructured":"Liu N, Yan M, Tao Q, Wu J, Chen J, Chen X, et\u00a0al. Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007146.","journal-title":"J Immunother Cancer"},{"key":"934_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05692-5","author":"N Liu","year":"2023","unstructured":"Liu N, Zhang J, Yan M, Chen L, Wu J, Tao Q, et\u00a0al. Supplementation with \u03b1-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1. Cell Death Dis. 2023. https:\/\/doi.org\/10.1038\/s41419-023-05692-5.","journal-title":"Cell Death Dis"},{"key":"934_CR61","unstructured":"Lo JA. Regulation of the inflamed tumor phenotype in melanoma immunotherapy. 2016."},{"issue":"1","key":"934_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00637-y","volume":"29","author":"L Martinkova","year":"2024","unstructured":"Martinkova L, Zatloukalova P, Kucerikova M, Friedlova N, Tylichova Z, Zavadil-Kokas F, et\u00a0al. Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1\/SOX10 regulatory axis. Cell Mol Biol Lett. 2024;29(1):117. https:\/\/doi.org\/10.1186\/s11658-024-00637-y.","journal-title":"Cell Mol Biol Lett"},{"key":"934_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121991","author":"HD Nguyen","year":"2019","unstructured":"Nguyen HD, Liao YC, Ho YS, Chen LC, Chang HW, Cheng TC, et\u00a0al. The \u03b19 nicotinic acetylcholine receptor mediates nicotine-induced PD-L1 expression and regulates melanoma cell proliferation and migration. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11121991.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"934_CR64","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1080\/21655979.2022.2029236","volume":"13","author":"X Pan","year":"2022","unstructured":"Pan X, Yi M, Liu C, Jin Y, Liu B, Hu G, et\u00a0al. Cilengitide, an \u03b1v\u03b23-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. Bioengineered. 2022;13(2):4557\u201372. https:\/\/doi.org\/10.1080\/21655979.2022.2029236.","journal-title":"Bioengineered"},{"issue":"4","key":"934_CR65","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.21873\/anticanres.16296","volume":"43","author":"K Sasaki","year":"2023","unstructured":"Sasaki K, Hirohashi Y, Murata K, Minowa T, Nakatsugawa M, Murai A, et\u00a0al. SOX10 inhibits T cell recognition by inducing expression of the immune checkpoint molecule PD-L1 in A375 melanoma cells. Anticancer Res. 2023;43(4):1477\u201384. https:\/\/doi.org\/10.21873\/anticanres.16296.","journal-title":"Anticancer Res"},{"key":"934_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133408","author":"KY Song","year":"2023","unstructured":"Song KY, Han YH, Roehrich H, Brown ME, Torres-Cabala C, Giubellino A. MET receptor tyrosine kinase inhibition reduces interferon-gamma (IFN-\u03b3)-stimulated PD-L1 expression through the STAT3 pathway in melanoma cells. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15133408.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"934_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03625-6","volume":"24","author":"R Sun","year":"2024","unstructured":"Sun R, Wei S, Yu Y, Wang Z, Yao T, Zhang Y, et\u00a0al. Prognostic value and immune infiltration of a tumor microenvironment-related PTPN6 in metastatic melanoma. Cancer Cell Int. 2024;24(1):435. https:\/\/doi.org\/10.1186\/s12935-024-03625-6. (PubMed PMID: 39732710; PubMed Central PMCID: PMC11682626).","journal-title":"Cancer Cell Int"},{"key":"934_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121963","author":"E Terzuoli","year":"2019","unstructured":"Terzuoli E, Bellan C, Aversa S, Ciccone V, Morbidelli L, Giachetti A, et\u00a0al. ALDH3A1 overexpression in melanoma and lung tumors drives cancer stem cell expansion, impairing immune surveillance through enhanced PD-L1 output. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11121963.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"934_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05394-6","volume":"12","author":"S Tong","year":"2022","unstructured":"Tong S, Cinelli MA, El-Sayed NS, Huang H, Patel A, Silverman RB, et\u00a0al. Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS). Sci Rep. 2022;12(1):1701. https:\/\/doi.org\/10.1038\/s41598-022-05394-6.","journal-title":"Sci Rep"},{"issue":"3","key":"934_CR70","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00262-021-03007-1","volume":"71","author":"A van Duijn","year":"2022","unstructured":"van Duijn A, Willemsen KJ, van Uden NOP, Hoyng L, Erades S, Koster J, et\u00a0al. A secondary role for hypoxia and HIF1 in the regulation of (IFN\u03b3-induced) PD-L1 expression in melanoma. Cancer Immunol Immunother. 2022;71(3):529\u201340. https:\/\/doi.org\/10.1007\/s00262-021-03007-1.","journal-title":"Cancer Immunol Immunother"},{"key":"934_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153725","volume":"229","author":"D Vu\u010dini\u0107","year":"2022","unstructured":"Vu\u010dini\u0107 D, Grahovac M, Grahovac B, Vitezi\u0107 BM, Kova\u010d L, Belu\u0161i\u0107-Gobi\u0107 M, et\u00a0al. PD-L1 expression is regulated by microphthalmia-associated transcription factor (MITF) in nodular melanoma. Pathol Res Pract. 2022;229:153725. https:\/\/doi.org\/10.1016\/j.prp.2021.153725.","journal-title":"Pathol Res Pract"},{"issue":"4","key":"934_CR72","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jid.2017.11.009","volume":"138","author":"YF Wang","year":"2018","unstructured":"Wang YF, Liu F, Sherwin S, Farrelly M, Yan XG, Croft A, et\u00a0al. Cooperativity of HOXA5 and STAT3 is critical for HDAC8 inhibition-mediated transcriptional activation of PD-L1 in human melanoma cells. J Invest Dermatol. 2018;138(4):922\u201332. https:\/\/doi.org\/10.1016\/j.jid.2017.11.009.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"934_CR73","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1158\/0008-5472.CAN-18-3134","volume":"79","author":"W Wang","year":"2019","unstructured":"Wang W, Chapman NM, Zhang B, Li M, Fan M, Laribee RN, et\u00a0al. Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-\u03baB contributes to UV radiation-induced immune suppression. Cancer Res. 2019;79(11):2909\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3134.","journal-title":"Cancer Res"},{"key":"934_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216861","volume":"590","author":"L Wang","year":"2024","unstructured":"Wang L, Liu X, Han Y, Tsai H, Dan Z, Yang P, et\u00a0al. TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma. Cancer Lett. 2024;590:216861. https:\/\/doi.org\/10.1016\/j.canlet.2024.216861.","journal-title":"Cancer Lett"},{"issue":"4","key":"934_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-03978-5","volume":"74","author":"C Wirbel","year":"2025","unstructured":"Wirbel C, Durand S, Boivin F, Plaschka M, Benboubker V, Grimont M, et\u00a0al. ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma. Cancer Immunol Immunother. 2025;74(4):141. https:\/\/doi.org\/10.1007\/s00262-025-03978-5.","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"934_CR76","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-21-2078","volume":"81","author":"S Yokoyama","year":"2021","unstructured":"Yokoyama S, Takahashi A, Kikuchi R, Nishibu S, Lo JA, Hejna M, et\u00a0al. SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 axis. Cancer Res. 2021;81(24):6131\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2078.","journal-title":"Cancer Res"},{"issue":"1","key":"934_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02559-z","volume":"41","author":"P Yu","year":"2022","unstructured":"Yu P, Wei H, Li K, Zhu S, Li J, Chen C, et\u00a0al. The traditional Chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun. J Exp Clin Cancer Res. 2022;41(1):346. https:\/\/doi.org\/10.1186\/s13046-022-02559-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"934_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02666-9","volume":"42","author":"H Zeng","year":"2025","unstructured":"Zeng H, Guo A, Liu Z, Xiang S, Zheng F. Isoliquiritigenin attenuates tumor progression and PD-L1 expression by inhibiting the phosphorylation of STAT3 in melanoma. Med Oncol. 2025;42(4):118. https:\/\/doi.org\/10.1007\/s12032-025-02666-9.","journal-title":"Med Oncol"},{"issue":"20","key":"934_CR79","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1039\/d1bm00724f","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhang Q, Xie J, Zhong Z, Deng C. Enzyme-responsive micellar JQ1 induces enhanced BET protein inhibition and immunotherapy of malignant tumors. Biomater Sci. 2021;9(20):6915\u201326. https:\/\/doi.org\/10.1039\/d1bm00724f. (PubMed PMID: 34524279).","journal-title":"Biomater Sci"},{"key":"934_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011611","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yu F, Ouyang J, Liu P, Dai Y, Wang Y, et\u00a0al. ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011611.","journal-title":"J Immunother Cancer"},{"issue":"36","key":"934_CR81","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1038\/s41388-018-0314-0","volume":"37","author":"B Zhu","year":"2018","unstructured":"Zhu B, Tang L, Chen S, Yin C, Peng S, Li X, et\u00a0al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene. 2018;37(36):4941\u201354. https:\/\/doi.org\/10.1038\/s41388-018-0314-0.","journal-title":"Oncogene"},{"issue":"4","key":"934_CR82","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et\u00a0al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017;20(4):854\u201367. https:\/\/doi.org\/10.1016\/j.celrep.2017.07.007.","journal-title":"Cell Rep"},{"issue":"28","key":"934_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201801120","volume":"14","author":"MZ Zou","year":"2018","unstructured":"Zou MZ, Liu WL, Li CX, Zheng DW, Zeng JY, Gao F, et\u00a0al. A multifunctional biomimetic nanoplatform for relieving hypoxia to enhance chemotherapy and inhibit the PD-1\/PD-L1 axis. Small. 2018;14(28):e1801120. https:\/\/doi.org\/10.1002\/smll.201801120.","journal-title":"Small"},{"issue":"1","key":"934_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0147-4","volume":"8","author":"M Lauss","year":"2015","unstructured":"Lauss M, Ringn\u00e9r M, Karlsson A, Harbst K, Busch C, Geisler J, et\u00a0al. DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Med Genomics. 2015;8(1):73. https:\/\/doi.org\/10.1186\/s12920-015-0147-4.","journal-title":"BMC Med Genomics"},{"issue":"5","key":"934_CR85","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-08-1361","volume":"15","author":"A Tanemura","year":"2009","unstructured":"Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MFG, Morton DL, et\u00a0al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res. 2009;15(5):1801\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1361.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"934_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.61","volume":"135","author":"M Lauss","year":"2015","unstructured":"Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, et\u00a0al. Genome-wide DNA methylation analysis in melanoma reveals the importance of CpG methylation in MITF regulation. J Invest Dermatol. 2015;135(7):1820. https:\/\/doi.org\/10.1038\/jid.2015.61.","journal-title":"J Invest Dermatol"},{"issue":"8\u20139","key":"934_CR87","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41417-021-00424-3","volume":"29","author":"L San Juan","year":"2022","unstructured":"San Juan L, Cagigal ML, Fernandez-Flores A, Mayorga M, Gandarillas A. Protooncogene MYC drives human melanocyte melanogenesis and senescence. Cancer Gene Ther. 2022;29(8\u20139):1160\u20137. https:\/\/doi.org\/10.1038\/s41417-021-00424-3.","journal-title":"Cancer Gene Ther"},{"issue":"49","key":"934_CR88","doi-asserted-by":"publisher","first-page":"33042","DOI":"10.1074\/jbc.273.49.33042","volume":"273","author":"ER Price","year":"1998","unstructured":"Price ER, Horstmann MA, Wells AG, Weilbaecher KN, Takemoto CM, Landis MW, et\u00a0al. \u03b1-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in waardenburg syndrome*. J Biol Chem. 1998;273(49):33042\u20137. https:\/\/doi.org\/10.1074\/jbc.273.49.33042.","journal-title":"J Biol Chem"},{"issue":"6","key":"934_CR89","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/pcmr.12596","volume":"30","author":"S Bang","year":"2017","unstructured":"Bang S, Won KH, Moon HR, Yoo H, Hong A, Song Y, et\u00a0al. Novel regulation of melanogenesis by adiponectin via the AMPK\/CRTC pathway. Pigment Cell Melanoma Res. 2017;30(6):553\u20137. https:\/\/doi.org\/10.1111\/pcmr.12596.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"934_CR90","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/pcmr.12802","volume":"32","author":"P Louphrasitthiphol","year":"2019","unstructured":"Louphrasitthiphol P, Ledaki I, Chauhan J, Falletta P, Siddaway R, Buffa FM, et\u00a0al. MITF controls the TCA cycle to modulate the melanoma hypoxia response. Pigment Cell Melanoma Res. 2019;32(6):792\u2013808. https:\/\/doi.org\/10.1111\/pcmr.12802.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"19","key":"934_CR91","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/onc.2011.425","volume":"31","author":"Y Cheli","year":"2012","unstructured":"Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, et\u00a0al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene. 2012;31(19):2461\u201370. https:\/\/doi.org\/10.1038\/onc.2011.425.","journal-title":"Oncogene"},{"key":"934_CR92","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2016.09.40","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Kirchberger MC, Walter L, Schuler G. Predicting the response to anti-PD1 therapy in metastatic melanoma. Transl Cancer Res. 2016. https:\/\/doi.org\/10.21037\/tcr.2016.09.40.","journal-title":"Transl Cancer Res"},{"key":"934_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1587545","author":"C Barrio-Alonso","year":"2025","unstructured":"Barrio-Alonso C, Nieto-Valle A, Barandalla-Revilla L, Avil\u00e9s-Izquierdo JA, Parra-Blanco V, S\u00e1nchez-Mateos P, et\u00a0al. Translating genetics into tissue: inflammatory cytokine-producing TAMs and PD-L1 tumor expression as poor prognosis factors in cutaneous melanoma. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1587545.","journal-title":"Front Immunol"},{"issue":"12","key":"934_CR94","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002322","volume":"48","author":"J Pineda-Reyes","year":"2024","unstructured":"Pineda-Reyes J, Arudra SK, Aung PP, Nagarajan P, Curry JL, Tetzlaff M, et\u00a0al. Dual PD-L1\/SOX10 immunohistochemistry combined with digital imaging enhances stratification accuracy of patients with metastatic melanoma. Am J Surg Pathol. 2024;48(12):1551. https:\/\/doi.org\/10.1097\/PAS.0000000000002322.","journal-title":"Am J Surg Pathol"},{"key":"934_CR95","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2025-0467-OA","author":"A Irfan","year":"2026","unstructured":"Irfan A, Khazaeli M, Milton DR, Nagarajan P, Cho WC, Lenskaya V, et\u00a0al. CD274 alterations and PD-L1 expression on tumor cells and tumor-infiltrating lymphocytes in patients with melanoma: relationships to histopathologic features and outcomes. Arch Pathol Lab Med. 2026. https:\/\/doi.org\/10.5858\/arpa.2025-0467-OA.","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"934_CR96","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1111\/jdv.20177","volume":"38","author":"G Geidel","year":"2024","unstructured":"Geidel G, Parnian N, Me\u00df C, Schlepper N, R\u00fcnger A, Heidrich I, et\u00a0al. Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma. J Eur Acad Dermatol Venereol. 2024;38(10):2017\u201323. https:\/\/doi.org\/10.1111\/jdv.20177.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"934_CR97","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1101\/gad.625811","volume":"25","author":"M Ohanna","year":"2011","unstructured":"Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, et\u00a0al. Senescent cells develop a PARP-1 and nuclear factor-\u03baB-associated secretome (PNAS). Genes Dev. 2011;25(12):1245\u201361. https:\/\/doi.org\/10.1101\/gad.625811.","journal-title":"Genes Dev"},{"issue":"11","key":"934_CR98","first-page":"2948","volume":"63","author":"V Sriuranpong","year":"2003","unstructured":"Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine\/paracrine stimulation of the interleukin 6\/gp130 cytokine system. Cancer Res. 2003;63(11):2948\u201356.","journal-title":"Cancer Res"},{"issue":"1","key":"934_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, et\u00a0al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy. Sig Transduct Target Ther. 2023;8(1):420. https:\/\/doi.org\/10.1038\/s41392-023-01647-6.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"934_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1403-9","volume":"38","author":"A Thiem","year":"2019","unstructured":"Thiem A, Hesbacher S, Kneitz H, di Primio T, Heppt MV, Hermanns HM, et\u00a0al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38(1):397. https:\/\/doi.org\/10.1186\/s13046-019-1403-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"934_CR101","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et\u00a0al. Defining a cancer dependency map. Cell. 2017;170(3):564-576.e16. https:\/\/doi.org\/10.1016\/j.cell.2017.06.010.","journal-title":"Cell"},{"issue":"2","key":"934_CR102","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29(2):25\u201338. https:\/\/doi.org\/10.7171\/jbt.18-2902-002.","journal-title":"J Biomol Tech"},{"issue":"15","key":"934_CR103","doi-asserted-by":"publisher","DOI":"10.1242\/dev.201266","volume":"151","author":"A Brombin","year":"2024","unstructured":"Brombin A, Patton EE. Melanocyte lineage dynamics in development, growth and disease. Development. 2024;151(15):dev201266. https:\/\/doi.org\/10.1242\/dev.201266.","journal-title":"Development"},{"issue":"51","key":"934_CR104","doi-asserted-by":"publisher","first-page":"49569","DOI":"10.1074\/jbc.M208915200","volume":"277","author":"M Tafani","year":"2002","unstructured":"Tafani M, Cohn JA, Karpinich NO, Rothman RJ, Russo MA, Farber JL. Regulation of intracellular pH mediates bax activation in HeLa cells treated with staurosporine or tumor necrosis factor-\u03b1*. J Biol Chem. 2002;277(51):49569\u201376. https:\/\/doi.org\/10.1074\/jbc.M208915200.","journal-title":"J Biol Chem"},{"issue":"5","key":"934_CR105","first-page":"1488","volume":"22","author":"A Benedetti","year":"1995","unstructured":"Benedetti A, Di Sario A, Svegliati Baroni G, Jezequel AM. Transforming growth factor beta 1 increases the number of apoptotic bodies and decreases intracellular pH in isolated periportal and perivenular rat hepatocytes. Hepatology. 1995;22(5):1488\u201398.","journal-title":"Hepatology"},{"key":"934_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1282653","author":"A Chattopadhyay","year":"2023","unstructured":"Chattopadhyay A, Jagdish S, Karhale AK, Ramteke NS, Zaib A, Nandi D. IFN-\u03b3 lowers tumor growth by increasing glycolysis and lactate production in a nitric oxide-dependent manner: implications for cancer immunotherapy. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1282653.","journal-title":"Front Immunol"},{"issue":"8","key":"934_CR107","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/glia.23168","volume":"65","author":"S Khakipoor","year":"2017","unstructured":"Khakipoor S, Ophoven C, Schr\u00f6dl-H\u00e4u\u00dfel M, Feuerstein M, Heimrich B, Deitmer JW, et\u00a0al. TGF-\u03b2 signaling directly regulates transcription and functional expression of the electrogenic sodium bicarbonate cotransporter 1, NBCe1 (SLC4A4), via Smad4 in mouse astrocytes. Glia. 2017;65(8):1361\u201375. https:\/\/doi.org\/10.1002\/glia.23168.","journal-title":"Glia"},{"issue":"1","key":"934_CR108","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jcb.21814","volume":"105","author":"Z Khalkhali-Ellis","year":"2008","unstructured":"Khalkhali-Ellis Z, Abbott DE, Bailey CM, Goossens W, Margaryan NV, Gluck SL, et\u00a0al. IFN-\u03b3 regulation of vacuolar pH, Cathepsin D processing and autophagy in mammary epithelial cells. J Cell Biochem. 2008;105(1):208\u201318. https:\/\/doi.org\/10.1002\/jcb.21814. (PubMed PMID: 18494001; PubMed Central PMCID: PMC2575810).","journal-title":"J Cell Biochem"},{"issue":"1","key":"934_CR109","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948333","volume":"21","author":"DA Raja","year":"2020","unstructured":"Raja DA, Gotherwal V, Burse SA, Subramaniam YJ, Sultan F, Vats A, et\u00a0al. pH\u2010controlled histone acetylation amplifies melanocyte differentiation downstream of MITF. EMBO Rep. 2020;21(1):e48333. https:\/\/doi.org\/10.15252\/embr.201948333.","journal-title":"EMBO Rep"},{"issue":"1","key":"934_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09956-9","volume":"22","author":"YJ Kwon","year":"2022","unstructured":"Kwon YJ, Seo EB, Jeong AJ, Lee SH, Noh KH, Lee S, et\u00a0al. The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells. BMC Cancer. 2022;22(1):852. https:\/\/doi.org\/10.1186\/s12885-022-09956-9.","journal-title":"BMC Cancer"},{"issue":"4","key":"934_CR111","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/pcmr.12762","volume":"32","author":"M Hejna","year":"2019","unstructured":"Hejna M, Moon WM, Cheng J, Kawakami A, Fisher DE, Song JS. Local genomic features predict the distinct and overlapping binding patterns of the bHLH-Zip family oncoproteins MITF and MYC-MAX. Pigment Cell Melanoma Res. 2019;32(4):500\u20139. https:\/\/doi.org\/10.1111\/pcmr.12762.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"46","key":"934_CR112","doi-asserted-by":"publisher","first-page":"45224","DOI":"10.1074\/jbc.M309036200","volume":"278","author":"WE Huber","year":"2003","unstructured":"Huber WE, Price ER, Widlund HR, Du J, Davis IJ, Wegner M, et\u00a0al. A tissue-restricted cAMP transcriptional response: SOX10 modulates \u03b1-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes. J Biol Chem. 2003;278(46):45224\u201330. https:\/\/doi.org\/10.1074\/jbc.M309036200.","journal-title":"J Biol Chem"},{"issue":"1","key":"934_CR113","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/pcmr.12922","volume":"34","author":"HN Vu","year":"2021","unstructured":"Vu HN, Dilshat R, Fock V, Steingr\u00edmsson E. User guide to MiT-TFE isoforms and post-translational modifications. Pigment Cell Melanoma Res. 2021;34(1):13\u201327. https:\/\/doi.org\/10.1111\/pcmr.12922.","journal-title":"Pigment Cell Melanoma Res"},{"key":"934_CR114","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.semcancer.2019.09.009","volume":"67","author":"CAC Williams","year":"2020","unstructured":"Williams CAC, Soufi A, Pollard SM. Post-translational modification of SOX family proteins: key biochemical targets in cancer? Semin Cancer Biol. 2020;67:30\u20138. https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.009.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"934_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01980-4","volume":"9","author":"L Wang","year":"2024","unstructured":"Wang L, Zhu Y, Zhang N, Xian Y, Tang Y, Ye J, et\u00a0al. The multiple roles of interferon regulatory factor family in health and disease. Sig Transduct Target Ther. 2024;9(1):282. https:\/\/doi.org\/10.1038\/s41392-024-01980-4.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"934_CR116","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41467-017-02354-x","volume":"9","author":"S Han","year":"2018","unstructured":"Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, et\u00a0al. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nat Commun. 2018;9(1):28. https:\/\/doi.org\/10.1038\/s41467-017-02354-x.","journal-title":"Nat Commun"},{"issue":"1","key":"934_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190834","volume":"13","author":"JC Cronin","year":"2018","unstructured":"Cronin JC, Loftus SK, Baxter LL, Swatkoski S, Gucek M, Pavan WJ. Identification and functional analysis of SOX10 phosphorylation sites in melanoma. PLoS ONE. 2018;13(1):e0190834. https:\/\/doi.org\/10.1371\/journal.pone.0190834.","journal-title":"PLoS ONE"},{"issue":"12","key":"934_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2130-z","volume":"10","author":"F Wang","year":"2019","unstructured":"Wang F, Sun F, Luo J, Yue T, Chen L, Zhou H, et\u00a0al. Loss of ubiquitin-conjugating enzyme E2 (Ubc9) in macrophages exacerbates multiple low-dose streptozotocin-induced diabetes by attenuating M2 macrophage polarization. Cell Death Dis. 2019;10(12):892. https:\/\/doi.org\/10.1038\/s41419-019-2130-z.","journal-title":"Cell Death Dis"},{"issue":"16","key":"934_CR119","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/onc.2016.380","volume":"36","author":"L Wang","year":"2017","unstructured":"Wang L, Ren J, Li G, Moorman JP, Yao ZQ, Ning S. LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required. Oncogene. 2017;36(16):2265\u201374. https:\/\/doi.org\/10.1038\/onc.2016.380.","journal-title":"Oncogene"},{"issue":"6664","key":"934_CR120","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/34681","volume":"391","author":"TJ Hemesath","year":"1998","unstructured":"Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391(6664):298\u2013301. https:\/\/doi.org\/10.1038\/34681.","journal-title":"Nature"},{"issue":"22","key":"934_CR121","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","volume":"78","author":"JM Hsu","year":"2018","unstructured":"Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res. 2018;78(22):6349\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1892.","journal-title":"Cancer Res"},{"issue":"1","key":"934_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04313-6","volume":"9","author":"JM Hsu","year":"2018","unstructured":"Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, et\u00a0al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9(1):1908. https:\/\/doi.org\/10.1038\/s41467-018-04313-6.","journal-title":"Nat Commun"},{"issue":"2","key":"934_CR123","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1755-148X.2010.00800.x","volume":"24","author":"B Bellei","year":"2011","unstructured":"Bellei B, Pitisci A, Catrical\u00e0 C, Larue L, Picardo M. Wnt\/\u03b2-catenin signaling is stimulated by \u03b1-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation. Pigment Cell Melanoma Res. 2011;24(2):309\u201325. https:\/\/doi.org\/10.1111\/j.1755-148X.2010.00800.x.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"934_CR124","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1172\/JCI95351","volume":"128","author":"J Nsengimana","year":"2018","unstructured":"Nsengimana J, Laye J, Filia A, O\u2019Shea S, Muralidhar S, Po\u017aniak J, et\u00a0al. \u03b2-Catenin\u2013mediated immune evasion pathway frequently operates in primary cutaneous melanomas. J Clin Invest. 2018;128(5):2048\u201363. https:\/\/doi.org\/10.1172\/JCI95351.","journal-title":"J Clin Invest"},{"issue":"1","key":"934_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170384","volume":"12","author":"Y Huang","year":"2017","unstructured":"Huang Y, Liu Y, Zheng C, Shen C. Investigation of cross-contamination and misidentification of 278 widely used tumor cell lines. PLoS ONE. 2017;12(1):e0170384. https:\/\/doi.org\/10.1371\/journal.pone.0170384.","journal-title":"PLoS ONE"},{"issue":"7428","key":"934_CR126","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/492186a","volume":"492","author":"JR Masters","year":"2012","unstructured":"Masters JR. End the scandal of false cell lines. Nature. 2012;492(7428):186\u2013186. https:\/\/doi.org\/10.1038\/492186a.","journal-title":"Nature"},{"issue":"6","key":"934_CR127","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10565-007-9019-9","volume":"23","author":"RM Nardone","year":"2007","unstructured":"Nardone RM. Eradication of cross-contaminated cell lines: a call for action. Cell Biol Toxicol. 2007;23(6):367\u201372. https:\/\/doi.org\/10.1007\/s10565-007-9019-9.","journal-title":"Cell Biol Toxicol"},{"issue":"6","key":"934_CR128","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1667\/RR15086.1","volume":"189","author":"JC Eckers","year":"2018","unstructured":"Eckers JC, Swick AD, Kimple RJ. Identity crisis \u2013 Rigor and reproducibility in human cell lines. Radiat Res. 2018;189(6):551\u20132. https:\/\/doi.org\/10.1667\/RR15086.1.","journal-title":"Radiat Res"},{"key":"934_CR129","doi-asserted-by":"publisher","unstructured":"Identity crisis. Nature. 2009;457(7232):935\u20136. https:\/\/doi.org\/10.1038\/457935b","DOI":"10.1038\/457935b"},{"issue":"1","key":"934_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.23233","volume":"122","author":"M Lacroix","year":"2008","unstructured":"Lacroix M. Persistent use of \u201cfalse\u201d cell lines. Int J Cancer. 2008;122(1):1\u20134. https:\/\/doi.org\/10.1002\/ijc.23233.","journal-title":"Int J Cancer"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00934-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00934-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00934-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:52:53Z","timestamp":1781830373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00934-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00934-8","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}